Syra Health (SYRA) Q3 2026 earnings summary

Executive summary

• Q3 record revenue was $2,557,295, up 52% YoY; net income was $344,610 versus a $225,902 loss, marking a third consecutive profitable quarter.

• Nine-month revenue was $7,225,238, up 32%; net income was $835,831 versus a $761,763 loss, and operating cash flow was $975,023.

Financial highlights

• Q3 gross profit was $1,185,041 versus $554,541; operating income was $300,002 versus an operating loss of $232,171; diluted EPS was $0.02 versus $(0.02).

• Q3 adjusted EBITDA was $301,725 versus a loss of $218,601.

• Nine-month gross profit was $3.22M versus $1.90M; operating income was $743K versus an operating loss of $769K.

• Nine-month net income included a $44,953 Indiana tax refund for a 2025 overpayment.

Outlook and guidance

• Management remained on track for full-year 2026 profitability after three consecutive profitable quarters.

• RFP- and contract-driven award timing, revenue recognition, and milestones may cause quarterly variability; delayed government awards and potential cancellations may weigh on near-term revenue and cash flows.

• Existing liquidity and expected sales were projected to be insufficient for at least 12 months from issuance; additional financing or expense reductions may be needed if sales fall short.